another imminent ii, page-15

Re the pipeline,

In early 2011, the only active VAST candidate was the opioid for pain relief.

The repiratory and obesity conditions were "suspended due to funding constraints"

Now the website refers to "multiple" conditions with "multiple pharmaceutical pertners" in addition to the opioid and respiratory work. They've also taken away reference to suspension of the respiratory work, suggesting it is now continuing.

HA-Doxorubicin and HA-5FU used to be on their website pipeline as HyDox and HyFive pre-2008, but were generalised to HyACT antibodies in preclinical stage in 2008, reintroduced as HyDox and HyFive again in 2009, changed back to HyACT antibodies in 2010, then removed altogether during 2011!

So its good to see them return in the Cowen presentation.

I agree ST... I'd like to see pipeline reference to preclinical work with others like HA-Erbitux and HA-Avastin.